Advertisement

Inflammation

, Volume 41, Issue 4, pp 1290–1296 | Cite as

Protective Effects of Isoliquiritigenin on LPS-Induced Acute Lung Injury by Activating PPAR-γ

  • Wenbin Zhang
  • Gui Wang
  • Shujun Zhou
ORIGINAL ARTICLE

Abstract

Isoliquiritigenin (ILG), a major ingredient of licorice, has been reported to have anti-oxidative and anti-inflammatory effects. The aim of this study was to investigate the protective effects of ILG on lung injury using an animal model of lipopolysaccharide (LPS)-induced acute lung injury (ALI). Male BALB/c mice were conditioned with ILG 1 h before intranasal instillation of LPS. The effects of ILG on lung injury were assessed by measuring lung histopathological examination, MPO assay, wet/dry (W/D) ratio, and inflammatory cytokine production. The results showed that ILG significantly inhibited LPS-induced lung histopathological changes and the MPO activity. Meanwhile, it attenuated the wet/dry (W/D) ratio in the lung tissues. The results also indicated that ILG inhibited LPS-induced ALI in the expression of inflammatory cytokines in the BALF. Furthermore, ILG can decrease the activity of NF-κB and can increase the expression of PPAR-γ. These findings suggested that ILG inhibited the inflammatory of LPS-induced lung injury by activating PPAR-γ and inhibiting NF-κB activation.

KEY WORDS

isoliquiritigenin LPS lung injury PPAR-γ 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Fein, A.M., and M.G. Calalang-Colucci. 2000. Acute lung injury and acute respiratory distress syndrome in sepsis and septic shock. Critical Care Clinics 16: 289–317.CrossRefPubMedGoogle Scholar
  2. 2.
    Grommes, J., and O. Soehnlein. 2011. Contribution of neutrophils to acute lung injury. Molecular Medicine 17: 293–307.CrossRefPubMedGoogle Scholar
  3. 3.
    Bersten, A.D., C. Edibam, T. Hunt, J. Moran, and Australian, New Zealand Intensive Care Society Clinical Trials G. 2002. Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian States. American Journal of Respiratory and Critical Care Medicine 165: 443–448.CrossRefPubMedGoogle Scholar
  4. 4.
    Goodman, R.B., J. Pugin, J.S. Lee, and M.A. Matthay. 2003. Cytokine-mediated inflammation in acute lung injury. Cytokine & Growth Factor Reviews 14: 523–535.CrossRefGoogle Scholar
  5. 5.
    Bhatia, M., and S. Moochhala. 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. The Journal of Pathology 202: 145–156.CrossRefPubMedGoogle Scholar
  6. 6.
    Kim, J.K., S.M. Oh, H.S. Kwon, Y.S. Oh, S.S. Lim, and H.K. Shin. 2006. Anti-inflammatory effect of roasted licorice extracts on lipopolysaccharide-induced inflammatory responses in murine macrophages. Biochemical and Biophysical Research Communications 345: 1215–1223.CrossRefPubMedGoogle Scholar
  7. 7.
    Kim, K.R., C.K. Jeong, K.K. Park, J.H. Choi, J.H. Park, S.S. Lim, and W.Y. Chung. 2010. Anti-inflammatory effects of licorice and roasted licorice extracts on TPA-induced acute inflammation and collagen-induced arthritis in mice. Journal of Biomedicine & Biotechnology 2010: 709378.Google Scholar
  8. 8.
    Kanazawa, M., Y. Satomi, Y. Mizutani, O. Ukimura, A. Kawauchi, T. Sakai, M. Baba, T. Okuyama, H. Nishino, and T. Miki. 2003. Isoliquiritigenin inhibits the growth of prostate cancer. European Urology 43: 580–586.CrossRefPubMedGoogle Scholar
  9. 9.
    Tawata, M., K. Aida, T. Noguchi, Y. Ozaki, S. Kume, H. Sasaki, M. Chin, and T. Onaya. 1992. Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. European Journal of Pharmacology 212: 87–92.CrossRefPubMedGoogle Scholar
  10. 10.
    Liu, S., L. Zhu, J. Zhang, J. Yu, X. Cheng, and B. Peng. 2016. Anti-osteoclastogenic activity of isoliquiritigenin via inhibition of NF-kappaB-dependent autophagic pathway. Biochemical Pharmacology 106: 82–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Kumar, S., A. Sharma, B. Madan, V. Singhal, and B. Ghosh. 2007. Isoliquiritigenin inhibits IkappaB kinase activity and ROS generation to block TNF-alpha induced expression of cell adhesion molecules on human endothelial cells. Biochemical Pharmacology 73: 1602–1612.CrossRefPubMedGoogle Scholar
  12. 12.
    Kim, J.Y., S.J. Park, K.J. Yun, Y.W. Cho, H.J. Park, and K.T. Lee. 2008. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages. European Journal of Pharmacology 584: 175–184.CrossRefPubMedGoogle Scholar
  13. 13.
    Takahashi, T., M. Baba, H. Nishino, and T. Okuyama. 2006. Cyclooxygenase-2 plays a suppressive role for induction of apoptosis in isoliquiritigenin-treated mouse colon cancer cells. Cancer Letters 231: 319–325.CrossRefPubMedGoogle Scholar
  14. 14.
    Shi, C., and E.G. Pamer. 2011. Monocyte recruitment during infection and inflammation. Nature Reviews. Immunology 11: 762–774.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Brigham, K.L. 2005. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Current Infectious Disease Reports 7: 327–328.CrossRefPubMedGoogle Scholar
  16. 16.
    Kolb, M., P.J. Margetts, D.C. Anthony, F. Pitossi, and J. Gauldie. 2001. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. The Journal of Clinical Investigation 107: 1529–1536.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Meduri, G.U., S. Headley, G. Kohler, F. Stentz, E. Tolley, R. Umberger, and K. Leeper. 1995. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107: 1062–1073.CrossRefPubMedGoogle Scholar
  18. 18.
    Meduri, G.U., G. Kohler, S. Headley, E. Tolley, F. Stentz, and A. Postlethwaite. 1995. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 108: 1303–1314.CrossRefPubMedGoogle Scholar
  19. 19.
    Hanada, T., and A. Yoshimura. 2002. Regulation of cytokine signaling and inflammation. Cytokine & Growth Factor Reviews 13: 413–421.CrossRefGoogle Scholar
  20. 20.
    Oeckinghaus, A., and S. Ghosh. 2009. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harbor Perspectives in Biology 1: a000034.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Rahman, I., and W. MacNee. 1998. Role of transcription factors in inflammatory lung diseases. Thorax 53: 601–612.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Everhart, M.B., W. Han, T.P. Sherrill, M. Arutiunov, V.V. Polosukhin, J.R. Burke, R.T. Sadikot, J.W. Christman, F.E. Yull, and T.S. Blackwell. 2006. Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. Journal of Immunology 176: 4995–5005.CrossRefGoogle Scholar
  23. 23.
    Chen, Y.C., J.S. Wu, H.D. Tsai, C.Y. Huang, J.J. Chen, G.Y. Sun, and T.N. Lin. 2012. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) and neurodegenerative disorders. Molecular Neurobiology 46: 114–124.CrossRefPubMedGoogle Scholar
  24. 24.
    Liu, D., B.X. Zeng, S.H. Zhang, Y.L. Wang, L. Zeng, Z.L. Geng, and S.F. Zhang. 2005. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats. Critical Care Medicine 33: 2309–2316.CrossRefPubMedGoogle Scholar
  25. 25.
    Ma, Z., W. Ji, Q. Fu, and S. Ma. 2013. Formononetin inhibited the inflammation of LPS-induced acute lung injury in mice associated with induction of PPAR gamma expression. Inflammation 36: 1560–1566.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Emergency DepartmentThe Third Affiliated Hospital of Soochow University, The First People’s Hospital of ChangzhouChangzhouChina
  2. 2.Department of Critical Care MedicineThe Third Affiliated Hospital of Soochow University, The First People’s Hospital of ChangzhouChangzhouChina

Personalised recommendations